The Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) is going up by 2.53% in today’s trading session, a rise equivalent to 0.29% of the stock’s price from yesterday’s market close. A news came out on 11/05/19 stating that Ironwood Pharmaceuticals to Present at the 28(th) Annual Credit Suisse Healthcare Conference by WSJ. The lowest point that the shares touched during the trading session was $11.175, while the peak of the day was recorded at a share price of $11.48. IRWD finished the previous session at $11.45 according to the data provided by Barchart, while the trading volume was observed to be $681637.
In the 100 days of trading, IRWD managed to top a 9.72% Moving average. Additionally, Ironwood Pharmaceuticals Inc. shares have achieved a 52-week range between 7.59 and 13.00 alongside 100 days raw stochastic set at 92.49%.
The number of shares outstanding, according to the fundamentals of the company, is set at 158.46M, equal to the value of $1.81B in market capitalization. In the last 30 days, Ironwood Pharmaceuticals Inc. shares went down by -0.81%, adding 11.76 to growth in value, on top of a +33.77% boost since 10/18/19.
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) Analyst’s Estimates
Ironwood Pharmaceuticals Inc. (IRWD) could record at least $0.22 per share in quarterly earnings in the upcoming report on 02/13/2020, a number that would actually represent an increase of 0.62 YOY.
According to the average analyst rating, Ironwood Pharmaceuticals Inc. would be rated as Overweight. Out of 8 different analysts monitoring IRWD stock, 3 analysts rate the stock as a BUY, 5 suggest to give the rating of HOLD, 0 indicate that IRWD is an OVERWEIGHT, 0 rated the stock as a SELL, and 0 analyst believes that the stock should be rated as UNDERWEIGHT.
On July 10, 2019, the stock earned a Resumed rating due to a new analyst call from Credit Suisse, while analysts from Morgan Stanley believe that the stock is set at Equal-Weight from Underweight, as concluded on March 27, 2019. H.C. Wainwright, is still rather wary about the stock, deciding to keep the rating at Neutral as confirmed through a call on February 25, 2019.
JP Morgan, on the other hand, provided a rather enthusiastic opinion on the rating, concluded in an analyst call on November 07, 2018, giving the stock a Underweight from the Neutral rating.
IRWD Key Ratios To Watch:
Taking in account the profitability of the Company, gross profit margin of +88.21% has been attained, while the operating margin has been recorded at -29.50%. The firm is also showcasing profitability through returns on assets in the company’s ownership, with ROA set at -60.22%. Beta value of the stock is recorded at 1.82. Additionally, Ironwood Pharmaceuticals Inc. is recording price volatility of 3.18% for the period of the last seven days and 3.68% in the last 30 days.
Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) Technical Outlook
For the period of the last 50 days, Ironwood Pharmaceuticals Inc. had its Raw Stochastic average set at 97.53% for the latest technical analysis. In comparison to the period of the last 20 days, the present Raw Stochastic average for the last 50 days poses as improvement, set at 96.81%. Stochastic %K for Ironwood Pharmaceuticals Inc., with the last 20 days included, was set at 92.40%, having Stochastic %D topping 93.52%. Based on the previous performance of the company for the mentioned period, there are more than several recorded moving trends. When it comes to the period of the last 12 months, accounting the time for year-to-date, price performance appears to be encouraging for Ironwood Pharmaceuticals Inc. stocks with recording 32.04% in metrics.
Ironwood Pharmaceuticals Inc. Insider Watch:
Similarly, 103.01% of the company’s float is held by institutions – and there are 215 institutions in total holding shares of this company. The top three institutional holders of IRWD stocks are: Wellington Management Company, LLP with ownership of $186.53 million, which is approximately 21727162 of the company’s shares; Brown Capital Management, Inc., holding 17930781 shares of the stock with an approximate value of $153.94 million; and Vanguard Group, Inc. (The), currently with more than 16745173 shares of the company valued at $143.76 million. Positions in Ironwood Pharmaceuticals Inc. stocks held by institutional investors has been changing actively in the past six months, a period during which there were 13 insider purchases amounting to 432407 shares. Similarly, there were 7 sale transactions amounting to 246209 shares, with the net shares purchased during the last six months reaching 186,198.